{"doi":"10.1002/ejhf.3043","title":"Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial","abstract":"AIM: COVID-19 may affect clinical risk in patients with heart failure. DELIVER began before and was conducted during the COVID-19 pandemic. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants. METHODS AND RESULTS: Participants with chronic heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) were randomized to dapagliflozin or placebo across 350 sites in 20 countries. COVID-19 was investigator-reported and the contribution of COVID-19 to death was centrally adjudicated. We assessed (i) the incidence of COVID-19, (ii) event rates before/during the pandemic, and (iii) risks of death after COVID-19 diagnosis compared to risks of death in participants without COVID-19. Further, we performed a sensitivity analysis assessing treatment effects of dapagliflozin vs. placebo censored at pandemic onset. Of 6263 participants, 589 (9.4%) developed COVID-19, of whom 307 (52%) required/prolonged hospitalization. A total of 155 deaths (15% of all deaths) were adjudicated as definitely/possibly COVID-19-related. COVID-19 cases and deaths did not differ by randomized assignment. Death rate in the 12 months following diagnosis was 56.1 (95% confidence interval [CI] 48.0-65.6) versus 6.4 (95% CI 6.0-6.8)/100 participant-years among trial participants with versus without COVID-19 (adjusted hazard ratio [aHR] 8.60, 95% CI 7.18-10.30). Risk was highest 0-3 months following diagnosis (153.5, 95% CI 130.3-180.8) and remained elevated at 3-6 months (12.6, 95% CI 6.6-24.3/100 participant-years). After excluding investigator-reported fatal COVID-19 events, all-cause death rates in the 12 months following diagnosis among COVID-19 survivors (n = 458) remained higher (aHR 2.46, 95% CI 1.83-3.33) than rates for all trial participants from randomization, with censoring of participants who developed COVID-19 at the time of diagnosis. Dapagliflozin reduced cardiovascular death/worsening HF events when censoring participants at COVID-19 diagnosis (HR 0.81, 95% CI 0.72-0.91) and pandemic onset (HR 0.72, 95% CI 0.58-0.89). There were no diabetic ketoacidosis or major hypoglycaemic events within 30 days of COVID-19. CONCLUSION: DELIVER is one of the most extensive experiences with COVID-19 of any cardiovascular trial, with >75% of follow-up time occurring during the pandemic. COVID-19 was common, with >50% of cases leading to hospitalization or death. Treatment benefits of dapagliflozin persisted when censoring at COVID-19 diagnosis and pandemic onset. Patients surviving COVID-19 had a high early residual risk. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03619213.","journal":"European Journal of Heart Failure","year":2023,"id":340236,"datarank":0.6906778168282752,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.2656958152198427,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.2656958152198427,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":16,"citers_with_citation_signal":11,"citers_with_endowment":11,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7152,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03619213"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":57284,"name":"Mikhail Kosiborod","orcid":"0000-0002-3750-9789","position":1,"is_corresponding":false},{"id":28286,"name":"Brian Claggett","orcid":"0000-0002-4215-9218","position":2,"is_corresponding":false},{"id":859433,"name":"Zi Michael Miao","orcid":"0000-0002-2377-1444","position":3,"is_corresponding":false},{"id":61406,"name":"Muthiah Vaduganathan","orcid":"0000-0003-0885-1953","position":4,"is_corresponding":false},{"id":49640,"name":"Carolyn S.P. Lam","orcid":"0000-0003-1903-0018","position":5,"is_corresponding":false},{"id":51666,"name":"Adrian F. Hernandez","orcid":"0000-0003-3387-9616","position":6,"is_corresponding":false},{"id":57285,"name":"Felipe A. Martínez","orcid":"0000-0002-5836-972X","position":7,"is_corresponding":false},{"id":57254,"name":"Silvio E. Inzucchi","orcid":"0000-0003-1254-6636","position":8,"is_corresponding":false},{"id":235994,"name":"Sanjiv J. Shah","orcid":"0000-0002-5655-8201","position":9,"is_corresponding":false},{"id":55735,"name":"Rudolf A. de Boer","orcid":"0000-0002-4775-9140","position":10,"is_corresponding":false},{"id":57280,"name":"Pardeep S. Jhund","orcid":"0000-0003-4306-5317","position":11,"is_corresponding":false},{"id":57261,"name":"Akshay S. Desai","orcid":"0000-0002-1443-0701","position":12,"is_corresponding":false},{"id":233711,"name":"James C. Fang","orcid":"0000-0003-2427-9504","position":13,"is_corresponding":false},{"id":882112,"name":"Yaling Han","orcid":"0000-0003-4569-6737","position":14,"is_corresponding":false},{"id":692626,"name":"Josep Comín‐Colet","orcid":"0000-0001-8780-720X","position":15,"is_corresponding":false},{"id":57289,"name":"Jarosław Dróżdż","orcid":"0000-0002-0732-2104","position":16,"is_corresponding":false},{"id":260473,"name":"Orly Vardeny","orcid":"0000-0002-6387-1351","position":17,"is_corresponding":false},{"id":2664,"name":"Béla Merkely","orcid":"0000-0001-6514-0723","position":18,"is_corresponding":false},{"id":262168,"name":"Daniel Lindholm","orcid":"0000-0003-3526-0614","position":19,"is_corresponding":false},{"id":1074600,"name":"Magnus Peterson","orcid":"0000-0001-9523-3971","position":20,"is_corresponding":false},{"id":226404,"name":"Anna Maria Langkilde","orcid":"0000-0002-1696-9356","position":21,"is_corresponding":false},{"id":2612,"name":"John J.V. McMurray","orcid":"0000-0002-6317-3975","position":22,"is_corresponding":false},{"id":27970,"name":"Scott D. Solomon","orcid":"0000-0003-3698-9597","position":23,"is_corresponding":false},{"id":231417,"name":"Ankeet S. Bhatt","orcid":"0000-0002-6449-4535","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-19T01:10:54.145367Z","pmid":"37771274","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}